Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma

by Mary H. Young, Greg Pietz, Elizabeth Whalen, Wilbert Copeland, Ethan Thompson, Brian A. Fox, Kathryn J. Newhall
Published 2021-08-01

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

by Kimberly H Harrington, Chelsea J Gudgeon, George S Laszlo, Kathryn J Newhall, Angus M Sinclair, Stanley R Frankel, Roman Kischel, Guang Chen, Roland B Walter
Published 2015-01-01

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

by Kristine A. Frerichs, Christie P. M. Verkleij, Meletios A. Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W. C. J. van de Donk
Published 2021-05-01